Haemonetics Stock Short Ratio
| HAE Stock | USD 85.43 0.51 0.60% |
Haemonetics fundamentals help investors to digest information that contributes to Haemonetics' financial success or failures. It also enables traders to predict the movement of Haemonetics Stock. The fundamental analysis module provides a way to measure Haemonetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Haemonetics stock.
Haemonetics | Short Ratio |
Haemonetics Company Short Ratio Analysis
Haemonetics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Haemonetics Short Ratio | 10.59 X |
Most of Haemonetics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Haemonetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Haemonetics Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Haemonetics is extremely important. It helps to project a fair market value of Haemonetics Stock properly, considering its historical fundamentals such as Short Ratio. Since Haemonetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Haemonetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Haemonetics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Haemonetics Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Haemonetics has a Short Ratio of 10.59 times. This is 171.54% higher than that of the Health Care Equipment & Supplies sector and 160.84% higher than that of the Health Care industry. The short ratio for all United States stocks is 164.75% lower than that of the firm.
Haemonetics Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Haemonetics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Haemonetics could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics of similar companies.Haemonetics is currently under evaluation in short ratio category among its peers.
Haemonetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Haemonetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Haemonetics' managers, analysts, and investors.Environmental | Governance | Social |
Haemonetics Institutional Holders
Institutional Holdings refers to the ownership stake in Haemonetics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Haemonetics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Haemonetics' value.| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 981.2 K | Schroder Investment Management Group | 2024-06-30 | 925.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 834 K | Westfield Capital Management Company, Lp | 2024-09-30 | 823.7 K | Btim Corp | 2024-09-30 | 809.6 K | Royal Bank Of Canada | 2024-06-30 | 791.7 K | Fmr Inc | 2024-09-30 | 774.5 K | Fisher Asset Management, Llc | 2024-09-30 | 689.5 K | Sg Capital Management, Llc | 2024-09-30 | 643.4 K | Blackrock Inc | 2024-06-30 | 6 M | Vanguard Group Inc | 2024-09-30 | 5.2 M |
Haemonetics Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0588 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 5.19 B | ||||
| Shares Outstanding | 50.22 M | ||||
| Shares Owned By Insiders | 0.89 % | ||||
| Shares Owned By Institutions | 99.11 % | ||||
| Number Of Shares Shorted | 5.16 M | ||||
| Price To Earning | 50.35 X | ||||
| Price To Book | 4.85 X | ||||
| Price To Sales | 3.13 X | ||||
| Revenue | 1.31 B | ||||
| Gross Profit | 530.77 M | ||||
| EBITDA | 262.1 M | ||||
| Net Income | 117.56 M | ||||
| Cash And Equivalents | 284.47 M | ||||
| Cash Per Share | 4.79 X | ||||
| Total Debt | 807.79 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 2.73 X | ||||
| Book Value Per Share | 17.44 X | ||||
| Cash Flow From Operations | 181.75 M | ||||
| Short Ratio | 10.59 X | ||||
| Earnings Per Share | 2.41 X | ||||
| Price To Earnings To Growth | 1.54 X | ||||
| Target Price | 110.8 | ||||
| Number Of Employees | 3.66 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 4.27 B | ||||
| Total Asset | 2.2 B | ||||
| Retained Earnings | 360.46 M | ||||
| Working Capital | 468.52 M | ||||
| Current Asset | 488.09 M | ||||
| Current Liabilities | 185.55 M | ||||
| Net Asset | 2.2 B |
About Haemonetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Haemonetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Haemonetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Haemonetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Haemonetics Piotroski F Score and Haemonetics Altman Z Score analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.